The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as
compared with placebo on measures of disease activity in patients with psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics